Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study
This article was originally published in The Pink Sheet Daily
Executive Summary
2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.
You may also be interested in...
Medicare Cancer Demo May Encourage Use Of EPO, Anti-Emetics
The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.